These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10821973)

  • 1. Live attenuated tetravalent dengue vaccine.
    Bhamarapravati N; Sutee Y
    Vaccine; 2000 May; 18 Suppl 2():44-7. PubMed ID: 10821973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
    Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
    Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
    Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
    Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.
    Kanesa-Thasan N; Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Coster TS; Kim-Ahn GJ; Dubois DR; Putnak JR; King A; Summers PL; Innis BL; Eckels KH; Hoke CH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):17-23. PubMed ID: 14740951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
    Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
    Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
    Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Eckels KH; Dubois DR; Summers PL; Hoke CH
    J Infect Dis; 1994 Dec; 170(6):1448-55. PubMed ID: 7995984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.
    Eckels KH; Dubois DR; Putnak R; Vaughn DW; Innis BL; Henchal EA; Hoke CH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):12-6. PubMed ID: 14740950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
    Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
    Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
    Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
    Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
    Huang CY; Kinney RM; Livengood JA; Bolling B; Arguello JJ; Luy BE; Silengo SJ; Boroughs KL; Stovall JL; Kalanidhi AP; Brault AC; Osorio JE; Stinchcomb DT
    PLoS Negl Trop Dis; 2013; 7(5):e2243. PubMed ID: 23738026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
    Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
    Halstead SB; Eckels KH; Putvatana R; Larsen LK; Marchette NJ
    Am J Trop Med Hyg; 1984 Jul; 33(4):679-83. PubMed ID: 6476215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.